Espoo, Finland

Jani C Mäenpää

This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignee: Pulseon Oy. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jani C Mäenpää. Retrieved from https://idiyas.com/inventor/jani-c-maenpaa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Jani C Mäenpää

Introduction

Jani C Mäenpää is a notable inventor based in Espoo, Finland. He has made significant contributions to the field of medical technology, particularly in the development of devices that monitor health conditions. With a total of 3 patents to his name, Mäenpää continues to push the boundaries of innovation.

Latest Patents

One of his latest inventions is an arrhythmia monitor, which is designed to detect irregular heartbeats. This device has the potential to improve patient outcomes by providing timely information to healthcare providers. The arrhythmia monitor exemplifies Mäenpää's commitment to enhancing medical technology.

Career Highlights

Mäenpää is currently associated with Pulseon Oy, a company that focuses on developing advanced health monitoring solutions. His work at Pulseon Oy has allowed him to collaborate with other experts in the field, further advancing his innovative projects.

Conclusion

Jani C Mäenpää is a prominent figure in the realm of medical inventions, particularly with his work on the arrhythmia monitor. His contributions to health technology are noteworthy and reflect his dedication to improving patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…